SALBUTAMOL nebuliser solution

Select language:
On this page

    Last updated: June 2023


    Prescription under medical supervision


    Therapeutic action

    • Short-acting beta-2 agonist bronchodilator 


    • Symptomatic treatment of severe asthma attack, in combination with ipratropium

    Forms and strengths

    • Solution for inhalation, in unit dose vial of 5 mg in 2.5 ml (2 mg/ml), to be administered via a nebuliser 

    Dosage and duration

    • Child under 5 years: 2.5 mg (1.25 ml) per nebulisation every 20 minutes for the first hour
    • Child 5 to 11 years: 2.5 to 5 mg (1.25 to 2.5 ml) per nebulisation every 20 minutes for the first hour
    • Child 12 years and over and adult: 5 mg (2.5 ml) per nebulisation every 20 minutes for the first hour


    • If symptoms do not improve, continue treatment every 20 minutes.
    • If symptoms improve, reduce gradually the frequency of nebulisations then change to salbutamol metered dose inhaler. 

    Contra-indications, adverse effects, precautions

    • May cause: headache, tremor and tachycardia, hyperglycaemia; hypokalaemia (after high doses).
    • Never use nebuliser solution by the parenteral route.
    • Pregnancy: no contra-indication
    • Breast-feeding: no contra-indication


    • Nebulised salbutamol should be reserved for severe asthma attacks. Otherwise, salbutamol should be delivered via a metered-dose inhaler with a spacer: administration is easier and faster, the treatment is as effective, or even more effective, than with a nebuliser and causes fewer adverse effects.
    • Volumes of nebuliser solution to be administered are insufficient to obtain efficient nebulisation in most nebulisers: dilute salbutamol solution with 0.9% sodium chloride to obtain a total volume of 4 ml in the reservoir of the nebuliser. Stop the nebulisation when the reservoir is empty (after around 10 to 15 minutes).


    –  Below 25 °C